Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacubitril-Valsartan in HFpEF and Secondary Mitral Valve Regurgitation
NCT05991284Phase 4Completed
- Sponsor
- Ziekenhuis Oost-Limburg
- Start
- Feb 2024
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of sacubitril + valsartan in heart failure with preserved ejection fraction (HFpEF), sponsored by Ziekenhuis Oost-Limburg. Started Feb 2024; status: completed.
02
Drugs
sacubitril + valsartan
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT05991284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05991284.